A Multicenter Open-Label Extension Study to Assess the Long-Term Safety Tolerability and Efficacy of Bimekizumab in the Treatment of Subjects with Active Psoriatic Arthritis

Brief description of study

The purpose of this study is to help us understand how safe, effective and tolerable an investigational new drug called bimekizumab (bye-me-key-zoo-mab) is for a long-term use in treating psoriatic arthritis. It will also help us understand how bimekizumab acts in your body and how your body reacts to bimekizumab. As you have been informed during your participation in your previous parent study (PA0010 [BE OPTIMAL] or PA0011 [BE COMPLETE]), bimekizumab is a new drug that may eventually be used in the treatment of psoriatic arthritis. It is investigational, which means that is it still being tested, and has not yet been approved for treatment by the health authorities. Bimekizumab is a new drug that may eventually be used in the treatment of psoriatic arthritis. It is investigational, which means that is it still being tested, and has not yet been approved for treatment by the health authorities.


Clinical Study Identifier: s19-00833
Principal Investigator: David H. Goddard.
Other Investigators: Jennifer Hill, Andres M. Piatti, Lauren E. Wong.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.